版本:
中国

BRIEF-Genmab A/S says Phase II study in NHL will not proceed

March 30 Genmab A/S :

* Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial

* Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed

* Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned

* Genmab says announcement has no impact on other ongoing or planned studies with daratumumab

* Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab

* Study will not proceed to stage 2 based on results of a data review

* Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn't reach predefined ORR futility thresholds

* In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐